Hepion Pharmaceuticals
Business Services · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5 Madison Ave Ste 400, Morristown, New J...Phone Number
(416) 699-5273Website
www.hepionpharma.comRevenue
-Stock Symbol
HEPAIndustry
About Hepion Pharmaceuticals
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical company focused on Artificial Intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. The Companys lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models and is currently in Phase 2 clinical development for the treatment of NASH.Explore more
Hepion Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Hepion Pharmaceuticals
Compare insights from companies similar to Hepion Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Hepion Pharmaceuticals Tech Stack
A closer look at the technologies used by Hepion Pharmaceuticals
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hepion Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical company focused on Artificial Intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. The Companys lead drug candidate, rencofilstat, is a... Read More
